Detemir as a once-daily basal insulin in type 2 diabetes

Scott E Nelson
Cleveland Family Medicine, Cleveland, Mississippi, USA

Background: Insulin detemir, a long-acting basal insulin analog, is labeled for once-daily or twice-daily dosing in patients with type 1 (T1DM) or type 2 (T2DM) diabetes mellitus. Protocols for some earlier clinical studies of detemir evaluated twice-daily dosing, which may have generated the misperception that detemir should be prescribed twice daily for most patients. This review examines pharmacokinetic and pharmacodynamic (PK/PD), observational, and controlled studies that have evaluated once-daily and twice-daily detemir in patients with T2DM to determine the efficacy and safety of once-daily dosing.

Methods: PubMed was searched using the keywords “detemir,” “once daily,” “twice daily,” and “type 2 diabetes” with the limits of clinical trial, human, and English.

Results: Detemir has a relatively flat time–action profile and duration of action of up to 24 hours for patients with T2DM. Once-daily dosing is the most commonly used detemir regimen reported in observational studies, and controlled clinical studies indicate that once-daily dosing controls glycosylated hemoglobin when detemir is administered alone or in combination with a prandial insulin or oral antidiabetes drugs. In comparative clinical trials, detemir had a similar time–action profile and duration of action to another long-acting insulin analog, glargine, with less within-subject variability. Once-daily detemir was associated with no weight gain or less weight gain than comparator regimens. For patients who had not achieved glycemic control with a basal dose of once-daily detemir, adding a prandial insulin provided better glycemic control, less postprandial hypoglycemia, and a lower total daily dose of detemir than twice-daily detemir. Involvement of a multidisciplinary team and the use of a holistic approach for the treatment of T2DM patients are recommended to achieve and maintain the best patient outcomes.

Conclusion: Results from PK/PD, observational, and controlled clinical studies support a once-daily detemir regimen alone or in combination with a prandial insulin or oral antidiabetes drugs.

Keywords: basal insulin, detemir, type 2 diabetes mellitus, pharmacokinetics, pharmacodynamics

Introduction

The joint American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD) 2009 consensus algorithm for initiation and adjustment of therapy for patients with type 2 diabetes mellitus (T2DM) recommends as tier 1 those treatments that have been shown to be well validated and that represent the most well-established and effective strategies.1 Tier 1/step 1 interventions recommended by ADA/EASD are lifestyle changes (to decrease weight and increase activity) and metformin therapy. If these interventions fail to achieve or sustain glycemic goals within 2–3 months, the recommended tier 1/step 2 intervention is to initiate treatment with insulin (intermediate or long-acting basal insulin) or a sulfonylurea. Adding or using...
other antidiabetes therapies is considered a tier 2 intervention (ie, a less well-validated treatment strategy). The ADA/EASD algorithm recommends the rapid addition of medications and transition to new regimens when target glycemic goals are not achieved or sustained, including the early addition of insulin therapy.1

The ADA 2011 “Standards of medical care” support using the ADA/EASD algorithm but prioritize treatments that achieve and maintain glycemic targets safely over the use of specific drug therapies in the exact algorithm sequence.2 Basal insulin therapy is regarded as the foundation insulin for building glycemic control, especially as a once-daily regimen. Currently available basal insulin therapies include intermediate-acting neutral protamine Hagedorn (NPH) and the long-acting basal insulin analogs glargine and detemir. NPH insulin is a crystalline suspension of human insulin with protamine and zinc that provides an intermediate-acting insulin with a slower onset of action and a longer duration of activity than regular human insulin.3 NPH insulin is used for the treatment of patients with T2DM or type 1 diabetes mellitus (T1DM). It has a peak of activity in 5–10 hours, resulting in a higher incidence of postprandial hypoglycemia than the long-acting insulin analogs, which display no peak effect.4 NPH insulin has an effective duration of 12–18 hours, and thus is administered twice daily for most patients. Similar to all insulin formulations, NPH insulin’s duration of action is dependent on dose, site of injection, blood supply, temperature, and physical activity.3 The addition of insulin to the treatment regimen of patients with T2DM is considered a step 2 option; however, because of the higher incidence of postprandial hypoglycemia and the need for twice-daily dosing, NPH is usually considered after longer-acting insulins.

Long-acting insulins such as glargine and detemir are effective for basal control of glucose, but do not target glucose fluctuations that occur after a meal.5 Rapid-acting insulins are more effective at controlling postprandial glucose concentrations. This is the rationale for adding rapid-acting bolus insulin before meals in patients receiving long-acting basal insulin who are above target postprandial glucose levels.

Glargine is a recombinant long-acting insulin analog that is US Food and Drug Administration (FDA) approved for patients with T2DM and T1DM.6 Molecular changes allow glargine to form microprecipitates in the neutral pH of subcutaneous tissue, and glargine is slowly released from these precipitates over the dosing interval. In patients with T2DM, subcutaneous absorption of insulin glargine was two to three times slower than NPH insulin as determined by disappearance of radio-labeled glargine from the injection site.7 For insulin glargine vs NPH insulin, the median time for 25% of the radioactivity to disappear was 15 vs 6.5 hours and for 75% to disappear was 42.4 vs 26.6 hours, respectively. The duration of action of subcutaneously administered glargine is up to 24 hours and it is administered once daily in most patients.6

Twice-daily dosing of glargine has been evaluated in patients with T1DM.4,10 According to a review by Devries et al glargine and detemir administered once daily both display a dose-dependent waning of glycemic effect, which necessitates twice-daily administration in some patients with T1DM.11 The rationale for this is that long-acting insulins administered once daily provide glycemic control for basal glucose production. All insulins display a dose-dependent effect and a relative dose-dependent duration of action. If the basal insulin dose is split, the total twice-daily dose of insulin is likely to be higher than the once-daily dose because the long-acting insulin will provide coverage for both basal and predinner glucose concentrations. To avoid twice-daily dosing of a basal insulin, a rapid-acting insulin should be added to the insulin regimen to cover prandial glucose concentrations.11 Although only reported for glargine in T1DM patients, a waning of glycemic effect requiring twice-daily administration likely occurs in patients with T2DM as well.11

Detemir is a biosynthetic long-acting insulin analog that is FDA-approved for patients with T2DM or T1DM. It is structurally modified to self-associate and bind reversibly to albumin and is soluble at a neutral pH.12,13 These characteristics mediate detemir’s slow absorption from the subcutaneous administration site and result in a protracted duration of action compared with conventional human insulin formulations. Detemir has a duration of action of up to 24 hours.14 It is soluble in subcutaneous tissue, which may be why detemir has reduced inter- and intrapatient variability compared with other agents, since precipitation and dissolution of a precipitate (required for NPH and glargine absorption) are unpredictable processes.15 The detemir prescribing information recommends that, for patients with T2DM or T1DM currently receiving only basal insulin, changing the basal insulin to detemir can be done on a unit-to-unit basis. For insulin-naive patients with T2DM who are inadequately controlled on oral antidiabetic drugs, detemir should be started at a dose of 0.1–0.2 units/kg once daily in the evening or 10 units once or twice daily, and the dose adjusted to achieve glycemic targets.14
In early studies of detemir, twice-daily dosing was used for direct comparison of detemir to NPH insulin and to seek an additional indication. Recent clinical studies support once-daily administration of detemir in combination with other antidiabetes therapies for most patients with T2DM. Despite this and the FDA-approval for once or twice-daily dosing, there are misconceptions that detemir should be administered twice daily for most patients. This review discusses studies that have evaluated twice-daily and once-daily dosing of detemir in patients with T2DM and addresses these misconceptions. To identify studies for this review, a search of PubMed was conducted for publications with the keywords “detemir,” “once daily,” “twice daily,” and “type 2 diabetes” using the limits of clinical trial, human, and English.

**Detemir pharmacokinetics and pharmacodynamics (PK/PD) in T2DM patients**

A randomized, double-blind, euglycemic clamp study of 27 overweight men with T2DM was conducted to compare the time–action profiles of detemir and glargine insulins.\(^\text{16}\) Using a continuous glucose monitoring system, both insulins displayed similar flat time–action profiles with no pronounced activity peaks, and a duration of action of up to 24 hours. Maximum glucose infusion rates (GIR\(_{\text{max}}\)) increased in linear fashion for both insulins. The GIR\(_{\text{max}}\) for detemir doses of 0.4, 0.8, and 1.4 units/kg were 0.9 \(\pm\) 0.6, 1.5 \(\pm\) 0.8, and 2.4 \(\pm\) 1.2 mg/kg/min, respectively. The GIR\(_{\text{max}}\) for glargine doses of 0.4, 0.8, and 1.4 units/kg were 0.8 \(\pm\) 0.8, 1.8 \(\pm\) 1.6, and 2.9 \(\pm\) 1.8 mg/kg/min, respectively. Both insulins displayed an increase in peak and total plasma levels with increasing dose. The durations of action of detemir and glargine were similar at comparable doses. In the high-dose (1.4 units/kg) detemir and glargine groups, the duration of action was 22 \(\pm\) 2.6 hours and 24 hours, respectively. With the clinically relevant low and medium doses (0.4 and 0.8 units/kg), the durations of action were comparable and estimated to be less than 24 hours for detemir and glargine insulins. Durations of action for detemir and glargine at the 0.4 units/kg dose were 12.0 \(\pm\) 8.5 and 10.2 \(\pm\) 7.4 hours, and for the 0.8 units/kg dose were 16.8 \(\pm\) 6.8 and 19.4 \(\pm\) 6.9 hours, respectively. In this analysis, duration of action was determined based on the GIR profile. Glucose clamp studies in patients with T2DM may not be effective in accurately detecting the duration of action since the fasting plasma glucose (FPG) level is supported by endogenous insulin secretion. Glucose clamp studies are more useful in determining within-patient variability. Detemir, an albumin-bound insulin, displayed significantly less within-patient variability than glargine (GIR\(_{\text{max}}\) [coefficient of variation, CV] 40\% vs 147\% for detemir and glargine, respectively; \(P < 0.001\)). Between-patient variability was similar between groups (GIR\(_{\text{max}}\) [CV] 66\% vs 46\% for detemir and glargine, respectively; \(P = \text{not significant (NS)}\)). Both insulins displayed an increase in the effect with increasing dose and a duration of action of up to 24 hours.

A more recent randomized, double-blind, crossover study of 29 men and women with T2DM also showed that detemir had a time–action profile, duration of action, and variation in glycemic effect similar to glargine as measured by continuous glucose monitoring.\(^\text{17}\) Patients had similar mean 24-hour blood glucose levels (133 \(\pm\) 21 vs 126 \(\pm\) 20 mg/dL detemir vs glargine; \(P = 0.385\)) and similar basal blood glucose levels (105 \(\pm\) 23 vs 98 \(\pm\) 19 mg/dL; \(P = 0.204\)). In addition, the mean dose of detemir once daily was similar to the glargine once-daily dose (26.3 vs 26.6 units/day; \(P = 0.837\)). Basal glucose control was achieved in all patients in a mean of 3.8 days for detemir and 3.5 days for glargine (\(P = 0.360\)).

PK/PD data support the efficacy of once-daily dosing of detemir. Questions regarding the accumulation of detemir, resulting in an increased metabolic effect, have also been addressed. According to Bott et al.,\(^\text{18}\) glucose clamp data indicate that detemir twice daily reaches steady state after the second injection, with no further increase of the metabolic effect thereafter.

**Clinical studies using detemir twice daily in T2DM patients**

Clinical studies have used a protocol of detemir administered only twice daily\(^\text{19}\) or once or twice daily\(^\text{20–23}\) to assess safety and efficacy compared with NPH or glargine insulins.

A randomized, treat-to-target trial was conducted to assess the safety and efficacy of adding basal insulin therapy (with twice-daily detemir or NPH insulin) to suboptimal oral antidiabetes drug therapy.\(^\text{19}\) Insulin-naive patients with T2DM (\(n = 475\)) had glycosylated hemoglobin A\(_1c\) (A\(_1C\)) values decrease by 1.8\% (8.6\% to 6.8\%) and 1.9\% (8.5\% to 6.6\%) in the detemir and NPH groups, respectively (\(P = \text{NS}\)). The risk of any type of hypoglycemic event and nocturnal hypoglycemia was reduced by 47\% and 55\%, respectively, with detemir compared with NPH insulin therapy (\(P < 0.001\) for both). Mean weight gain was significantly less with detemir (1.2 kg) than NPH insulin therapy (2.8 kg; \(P < 0.001\)). Detemir twice daily showed similar glycemic control with less hypoglycemia and less weight gain compared with NPH twice daily.

**Glucose clamp studies**

Glucose clamp studies are more useful in determining within-patient variability. Detemir, an albumin-bound insulin, displayed significantly less within-patient variability than glargine (GIR\(_{\text{max}}\) [coefficient of variation, CV] 40\% vs 147\% for detemir and glargine, respectively; \(P < 0.001\)). Between-patient variability was similar between groups (GIR\(_{\text{max}}\) [CV] 66\% vs 46\% for detemir and glargine, respectively; \(P = \text{not significant (NS)}\)). Both insulins displayed an increase in the effect with increasing dose and a duration of action of up to 24 hours.
The safety and efficacy of a basal-bolus regimen of detemir (once or twice daily) or NPH in combination with prandial insulin were compared in 505 patients with T2DM.20 Following 26 weeks of treatment, significant reductions in A1C from baseline were observed in both groups (detemir 0.2%; \( P = 0.004 \) and NPH 0.4%; \( P < 0.001 \)). The number of injections of detemir did not significantly change A1C levels (\( P = 0.50 \)). At the end of the treatment period, 39% and 61% of patients were receiving detemir once daily and twice daily, respectively; 41% and 59% were receiving NPH once daily and twice daily, respectively. Detemir administration was associated with less weight gain than NPH. The mean change in body weight (adjusted for baseline weight and country) was 1.0 kg for detemir and 1.8 kg for NPH insulin (\( P = 0.017 \) between groups). Significantly less within-subject variability in day-to-day fasting self-monitored blood glucose was reported with detemir than with NPH insulin. The mean self-measured FPG concentrations were 7.5 mmol/L (135.0 mg/dL) and 7.6 mmol/L (136.8 mg/dL), respectively; and standard deviation (SD) (CV%) were 1.3 (17.6%) and 1.4 (18.5%), respectively (\( P = 0.021 \)).20 The reduced variability is likely due to more consistent release of detemir because, unlike NPH insulin, detemir remains in solution in subcutaneous tissue and does not rely on dissolution of the insulin precipitates for absorption.15 Less within-subject glycemic variability could reduce the risk of glucose excursions and the lack of a peak effect reduces the likelihood of postprandial hypoglycemic events.15

An open-label, treat-to-target trial was conducted to compare detemir once daily or twice daily with glargine (1:1 detemir to glargine) in a basal-bolus regimen in 319 patients with T2DM.22 Exploratory analyses were conducted on trial completers (\( n = 257 \)) to compare once-daily detemir to glargine. The mean decrease in A1C was 1.61% and 1.79% in once-daily detemir and glargine-treated patients, respectively. Overall incidence of hypoglycemia and within-patient variability were similar between groups. The mean weight gain was 3.1 kg and 4.2 kg for once-daily detemir and glargine-treated patients, respectively. The relative risk (RR) of nocturnal hypoglycemia was similar with once-daily and twice-daily administered detemir and glargine (once-daily RR 0.63 [95% confidence interval (CI) 0.37–1.06] and twice-daily RR 1.15 [0.68–1.94]). Basal insulin doses were 0.69 and 0.95 units/kg daily for patients receiving detemir once daily and twice daily, respectively; the glargine dose was 0.59 units/kg daily. The higher basal dose in the detemir group may have been a result of the protocol, which allowed detemir-treated patients to be switched from once to twice-daily dosing based on an elevated predinner glucose measurement. A post hoc analysis revealed that if the glargine cohort had been allowed to follow the same dosing protocol, 83.8% would have met criteria to switch to twice-daily dosing. The same analysis applied to the detemir group revealed that 82.7% of patients should have received twice-daily dosing rather than the 57.2% that actually did receive this regimen. Therefore, adding a second dose of a basal insulin because of an elevated predinner glucose concentration would result in a large number of patients switching to a twice-daily dosing regimen that offers little to no clinical advantage over once-daily dosing.

A randomized, treat-to-target trial was conducted in 582 insulin-naive patients with T2DM administered once or twice-daily detemir or glargine (1:1 detemir to glargine) in combination with oral antidiabetes drugs.21 By the end of the 52-week study, 45% (\( n = 104 \)) of detemir-treated patients were receiving detemir once daily and 55% (\( n = 129 \)) twice daily. Glycemic control was similar between groups. The mean A1C was 7.12% and 7.06% for patients receiving once-daily and twice-daily detemir, respectively, and was 7.12% for glargine-treated patients (\( P = \text{NS} \) for detemir vs glargine). The mean clinic FPG was 7.27 mmol/L (130.86 mg/dL) and 6.73 mmol/L (121.14 mg/dL) for patients receiving once-daily and twice-daily detemir, respectively; and 6.98 mmol/L (125.64 mg/dL) for glargine-treated patients (\( P = \text{NS} \) for detemir vs glargine). The variation in glycemic control prebreakfast (within-participant SD 1.06 mmol/L [19.1 mg/dL] vs 1.03 mmol/L [18.5 mg/dL]; \( P = 0.45 \)) and predinner (1.60 mmol/L [28.8 mg/dL] vs 1.55 mmol/L [27.9 mg/dL]; \( P = 0.41 \)) was similar between detemir and glargine groups, respectively. The mean daily dose of detemir was 0.52 units/kg and 1.00 units/kg for once-daily and twice-daily dosing, respectively; the mean daily dose of glargine was 0.44 units/kg. Weight gain was significantly lower in patients administered detemir compared with glargine; the mean change in weight for patients who completed the study (\( n = 482 \)) was 3.0 vs 3.9 kg, respectively (\( P = 0.01 \)). Patients receiving once-daily detemir gained significantly less weight than those receiving twice-daily dosing (mean weight change 2.3 vs 3.7 kg, respectively; \( P < 0.001 \)).

A randomized, treat-to-target study compared the efficacy and safety of detemir with glargine in a basal-bolus regimen in 385 patients with T2DM.23 At 26 weeks, detemir and glargine had similar A1C reductions, and results met the noninferiority criterion (least squares mean [detemir-glargine]: 0.207; 95% CI, 0.0149–0.3995). At 26 weeks, the least squares mean (standard error, ±SE) A1C values
were 7.13% ± 0.073% for detemir and 6.92% ± 0.091% for glargine-treated patients (P = 0.035); the least squares mean FPG concentrations were 7.22 mmol/L (129.7 mg/dL) and 7.44 mmol/L (134.3 mg/dL), respectively (P = 0.397). Significantly less weight gain was observed in detemir than glargine-treated patients (1.2 ± 3.96 vs 2.7 ± 3.94 kg, respectively; P = 0.001). The risk of hypoglycemia was comparable between groups and there was no difference in within-patient variability. Detemir once daily was the regimen used in 87.4% throughout the study. The mean doses of insulin were similar between groups (0.81 and 0.75 units/kg for detemir and glargine, respectively; P = 0.1).

Taken together, the results of these studies suggest that, initially, basal insulin (including detemir) may be administered once daily and that the dose should be increased until the desired FPG level has been achieved.24 If the desired predinner target blood glucose level cannot be achieved, the total dose of basal insulin may be divided and administered as two separate injections (morning and evening). However, twice-daily dosing of a basal insulin may not provide the needed glycemic and clinical benefits, and the general understanding is that once-daily dosing is preferred by patients and is associated with better medication adherence than more frequent dosing.5

**Optimizing detemir therapy: designs of clinical studies utilizing detemir once daily in T2DM**

More recent studies evaluating detemir in patients with T2DM have tended to use basal-bolus regimens for patients with limited or no β-cell function and basal-oral therapy for patients initiating insulin. Most of these detemir studies evaluated once-daily dosing.25–29 All studies discussed below are randomized controlled studies except for Predictable Results and Experience in Diabetes through Intensification and Control to Target: an International Variability Evaluation (PREDICTIVE), which is an observational study.

Three randomized, controlled studies evaluated the efficacy of once daily. The first, PREDICTIVE BMI27 was a 26-week, randomized, controlled trial of 277 overweight or obese adults with uncontrolled T2DM (A1C 7.5%–11.0%, body mass index [BMI] 25–40 kg/m²). Patients received either detemir or NPH insulin in the evening and insulin aspart at main meals and were allowed to continue taking metformin. At 26 weeks, equivalent glycemic control was reported for both treatment groups. The mean A1C value decreased from 8.9% to 7.8% with once-daily detemir and from 8.8% to 7.8% with NPH insulin therapy (P = NS between-treatment difference). The mean FPG concentration decreased to 8.8 ± 2.7 mmol/L (158.7 ± 48.6 mg/dL) and 8.9 ± 3.1 mmol/L (160.2 ± 55.8 mg/dL) in the detemir and NPH groups, respectively (P = NS between-treatment difference). However, significantly less weight gain (0.4 kg) was reported with detemir than with NPH (1.9 kg; P < 0.0001), and the risk of a hypoglycemic event was significantly lower with detemir compared with NPH (RR 0.62 [all events] and 0.43 [nocturnal]; P < 0.0001 for both). The authors concluded that once-daily detemir was effective as part of a basal-bolus regimen for patients with T2DM.

In the second study, a randomized, open-label, multicenter trial of 504 patients with poorly controlled T2DM was conducted at 91 centers across Europe and the USA.28 Patients were randomized to either once-daily morning detemir, once-daily evening detemir, or once-daily evening NPH (1:1:1) for 20 weeks. Glycemic control was similar among the detemir and NPH groups, with significantly better glycemic control with evening compared with morning detemir administration. The end of study mean A1C values were 7.5%, 7.4%, and 7.35% for morning detemir, evening detemir, and evening NPH, respectively; and the mean FPG was 8.61 mmol/L (154.98 mg/dL), 7.17 mmol/L (129.06 mg/dL), and 7.77 mmol/L (139.86 mg/dL), respectively (P < 0.001 morning vs evening detemir). Compared with NPH, evening detemir resulted in 53% (P = 0.019) and 65% (P = 0.031) less 24-hour and nocturnal hypoglycemia, respectively. Evening detemir and NPH insulin led to a weight gain of 0.7 and 1.6 kg, respectively (P = 0.005). Results indicate that detemir given once daily improves glycemic control similar to NPH but may be better tolerated at comparable doses.

The third trial, Treat to Target with Once-daily Insulin Therapy: Reduce A1C by Titrating Effectively (TITRATE)28 is a 20-week, randomized, controlled, open-label, multicenter, treat-to-target study. Insulin-naive patients (n = 244) with T2DM received once-daily detemir therapy and were randomized to one of two treatment arms, with doses titrated to achieve target FPG concentrations of 70–90 mg/dL (3.9–5.0 mmol/L) or 80–110 mg/dL (4.4–6.1 mmol/L). Once-daily detemir dosing followed the patient self-adjusted algorithm (303 algorithm) described below. The majority of patients in both groups achieved the ADA target A1C of <7% by the end of the study (64.3% and 54.5% for the 70–90 mg/dL [3.9–5.0 mmol/L] or 80–110 mg/dL [4.4–6.1 mmol/L] groups, respectively), and overall, low rates of hypoglycemia were reported (7.73 and 5.27 events/patient/year, respectively). Lowering the fasting
glucose levels using a self-directed titration algorithm with once-daily detemir was associated with low rates of hypo-
glycemia and increased the likelihood of achieving the

target A1C level. By the end of the study, the A1C value in the

70–90 mg/dL arm was 6.77%, which is the lowest end of

study A1C in a treat-to-target trial with any once-daily basal

analogue therapy.

Recently, the addition of prandial (bolus) insulin and
detemir to oral therapy was evaluated. The Treat to Target

in Type 2 Diabetes (4-T) study is a 3-year, open-label, multi-
center trial of 708 patients randomly assigned to receive

biphasic insulin aspart twice daily, prandial insulin aspart

three times daily, or basal detemir once daily (or twice, if

required), added to suboptimal therapy with metformin and

a sulfonylurea. Most patients required the addition of

aspart in the second and third year of study. All patients

treated with basal and prandial insulin-based regimens (such
detemir + aspart) achieved better A1C control than those

receiving biphasic insulin after the end of the study. The

median A1C levels (6.9%; 95% CI 6.8%–7.1%; P = 0.28

overall comparison) were similar after 1 year of use for all

groups and remained stable at the end of the study. Among

patients with a baseline A1C ≤ 8.5%, patients in the

biphasic group were less likely to achieve an A1C ≤ 6.5% compared with those in the prandial group (odds ratio [OR] 0.48; 95% CI 0.28–0.82; P = 0.007) or basal group (OR 0.46; 95% CI 0.27–0.78; P = 0.004). Detemir therapy

was associated with fewer hypoglycemic events. Median

numbers of hypoglycemic events per patient per year dur-
ing the study were biphasic group, 3; prandial group, 5.5;

and detemir group, 1.7. After 3 years, less weight gain

was observed in the basal group (3.6 ± 0.5 kg) than in the

biphasic (5.7 ± 0.5 kg) or prandial (6.4 ± 0.5 kg) insulin

groups (P < 0.01 for biphasic vs basal and prandial vs

basal groups). More patients in the biphasic insulin group

were taking sulfonylurea therapy at the end of the study

compared with the other study groups, which may explain

the increased weight gain and hypoglycemic events and

smaller A1C reduction in the biphasic group. The median
daily insulin dose increased during the second and third

study years and was similar for patients receiving prandial

or basal insulin therapy (105 units/day [95% CI 91–119] vs

105.5 units/day [95% CI 90–212], respectively; P = 0.26).

After 1 year, about two thirds of patients receiving detemir

were maintained with once-daily injections. Most patients

required the addition of prandial insulin by the second

and third year of study. Perhaps if more patients had received

basal-bolus therapy during the first year of therapy, more

patients could have achieved the A1C target of ≤6.5%,
Detemir as a once-daily basal insulin in type 2 diabetes

Table 1 Summary of PREDICTIVE subgroup analyses by country/region for type 2 diabetes patients

<table>
<thead>
<tr>
<th>Cohort</th>
<th>Patients, duration, and treatment</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>French</td>
<td>N = 329 52 weeks Detemir + OAD (n = 263) or detemir + bolus insulin (n = 66)</td>
<td>• Once-daily detemir + OAD change from baseline in A1C was −1.01% ± 1.48%; BID dosing was −0.66% ± 1.51% (P &lt; 0.01 for both); • Once-daily detemir + bolus insulin change from baseline in A1C was −0.73% ± 1.78% (P = 0.019); BID dosing was −0.22% ± 0.87% (P = NS); • Once-daily detemir + OAD change from baseline in FPG was −2.73 ± 3.07 mmol/L (−49.14 ± 55.26 mg/dL) (P &lt; 0.0001); BID dosing was −0.10 ± 2.66 mmol/L (−1.8 ± 47.88 mg/dL) (P = NS); • Once-daily detemir + bolus insulin change from baseline in FPG was −1.88 ± 4.81 mmol/L (−33.84 ± 86.58 mg/dL) (P = 0.062); BID dosing was −1.02 ± 2.44 mmol/L (−18.38 ± 43.92 mg/dL) (P = NS); • Once-daily detemir + OAD change in weight from baseline was 0.0 ± 4.9 kg; BID dosing was −0.2 ± 3.9 kg (P = NS for both); • Once-daily detemir + bolus insulin change in weight from baseline was 1.0 ± 4.8 kg; BID dosing was 0.1 ± 7.2 kg (P = NS for both); • Once-daily detemir + OAD change in total hypoglycemia events/patient/year from baseline was −7.02 (P = 0.0014); BID dosing was −8.58 (P = NS); • Once-daily detemir + bolus insulin change in total hypoglycemia events/patient/year from baseline was −1.43; BID dosing was −15.99 (P = NS for both); • Once-daily detemir + OAD associated with lower total detemir dose (0.35 ± 0.16 units/kg) than BID detemir dosing (0.74 ± 0.30 units/kg) at end of study; • 84% (222/263) of detemir + OAD-treated patients received once-daily detemir; none were converted to BID; • 84% (37/44) of detemir + bolus-treated patients who started on once-daily detemir were receiving this regimen at the end of the study.</td>
</tr>
<tr>
<td>German</td>
<td>N = 1832 3 months Transferred to detemir ± OAD from an OAD-only (n = 1321), NPH ± OAD (n = 251), or glargine ± OAD (n = 260)</td>
<td>• Change in A1C from baseline for switch from OAD-only was −1.29% ± 0.03%; for NPH ± OAD was −0.60% ± 0.09%; and for glargine was −0.59% ± 0.06% (P &lt; 0.0001 for all); • Change in FPG for OAD-only was −3.22 ± 0.67 mmol/L (−58.1 ± 1.2 mg/dL), for NPH ± OAD was −1.62 ± 0.18 mmol/L (−29.1 ± 3.2 mg/dL), and for glargine ± OAD was −1.37 ± 0.16 mmol/L (−24.6 ± 2.8 mg/dL) (P &lt; 0.0001 for all); • Change in weight for OAD-only was −0.9 ± 0.1 kg, for NPH ± OAD was −0.9 ± 0.3 kg, and for glargine ± OAD was −0.8 ± 0.2 kg (P &lt; 0.01 for all); • Change in total hypoglycemic events/patient/year was −2.7 (P &lt; 0.0001); • Once-daily detemir was used in 79% of patients.</td>
</tr>
<tr>
<td>Danish</td>
<td>N = 77 3 months Detemir + bolus insulin</td>
<td>• Change in A1C from baseline was −0.3% ± 1.1% (P = NS); • Change in FPG was −2.7 ± 3.9 mmol/L (48.6 ± 70.2 mg/dL) (P = NS); • Change in weight was −1.0 kg (P = 0.04); • Mean change in the incidence of total hypoglycemic episodes was −17.7 episodes/patient/year (P = 0.0012); • Detemir used once daily in 49% and twice daily in 34% of patients; data were missing for remaining patients.</td>
</tr>
<tr>
<td>European</td>
<td>N = 2377 14.4 weeks Detemir ± OADs, insulin-naive</td>
<td>• Change in A1C from baseline was −1.3 ± 1.3% (P &lt; 0.0001); • Change in FPG/FBG was −3.7 ± 3.3 mmol/L (−66.6 ± 59.4 mg/dL) (P &lt; 0.0001); • Within-subject FPG/FBG variability was −0.5 ± 1.2 mmol/L (−9.0 ± 21.6 mg/dL) (P &lt; 0.0001); • Change in body weight was −0.7 ± 3.5 kg (P &lt; 0.0001); reductions in body weight most apparent in patients with a higher baseline BMI; • 13% of patients reported weight loss of &gt; 3 kg at the end of study; • Change in mean number of hypoglycemic episodes per patient year was −0.3 (P = 0.27); • Mean daily dose of detemir was 22 units; • Detemir used once daily in 82% of patients.</td>
</tr>
</tbody>
</table>

Note: *Fasting blood glucose or fasting plasma glucose, depending on glucose meter used.*

**Abbreviations:** A1C, glycosylated hemoglobin A1c; BID, twice daily; BMI, body mass index; FBG, fasting blood glucose; FPG, fasting plasma glucose; NS, not significant; OAD, oral antidiabetes drug; PREDICTIVE, Predictable Results and Experience in Diabetes through Intensification and Control to Target: an International Variability Evaluation.

be more effective at adjusting the insulin regimen than standard-of-care practices. Hypoglycemia rates decreased significantly from baseline to end of study, from 9.05 to 6.44 events/patient/year for the 303 algorithm group (P < 0.0039) and from 9.53 to 4.95 for the standard-of-care group (P < 0.0001). Results from PREDICTIVE 303 indicate that self-adjusted dosing and once-daily dosing of detemir is effective.
A post hoc subgroup analysis that evaluated insulin-naive patients in the PREDICTIVE 303 study found that by study end, 95% of patients in the 303 algorithm group remained on once-daily detemir and were able to effectively implement the 303 algorithm to achieve improvements in glycemic control. These results are consistent with the findings from the observational PREDICTIVE study conducted in Europe.

Two additional subgroup analyses of European cohorts of PREDICTIVE were conducted and suggested that switching to once-daily detemir from NPH or glargine therapy is associated with significantly improved glycemic control. In a cohort of 777 patients with T2DM, Yenigun and Honka found that switching from once or twice-daily glargine to once-daily detemir was associated with a significant reduction in A1C from baseline (0.51% and 0.89%, respectively; \( P < 0.05 \) for both groups). The mean reduction in FPG was significant in the once-daily and twice-daily to once-daily transition groups (1.63 ± 2.42 [29.3 ± 43.56] and 1.91 ± 2.35 [34.4 ± 42.3] mmol/L [mg/dL], respectively; \( P < 0.05 \)). The mean reduction in body weight from baseline was significant in the once-daily to once-daily transition group (0.3 ± 3.2 kg; \( P < 0.05 \) but not in the twice-daily to once-daily transition group (0.3 ± 1.7 kg; \( P = \text{NS} \)). Similar results were observed by Sreenan et al., when transitioning from NPH to once-daily detemir. A cohort of 2137 patients with T2DM was evaluated. The mean reduction in A1C was 0.56% for both groups (\( P < 0.001 \) from baseline for both) transitioning from once or twice-daily NPH. The mean change from baseline in FPG was significantly reduced when patients transitioned from NPH to detemir (1.63 [29.34] and 1.91 [34.38] mmol/L [mg/dL] for the once-daily to once-daily and the twice-daily to once-daily transition groups, respectively; \( P < 0.05 \) for both groups). Switching to once-daily detemir from once-daily NPH decreased the overall rate of hypoglycemic events by 10.2 episodes/patient year (\( P < 0.001 \)) and from twice-daily NPH it decreased the rate by 11.3 (\( P < 0.001 \)). The daily dose of detemir at the end of study was 8.1 units less per day than the prestudy NPH twice-daily dose, and was 4 units higher than the prestudy NPH once-daily dose.

The significant reduction in weight observed with detemir in comparison to NPH in clinical studies has not been explained by differences in the incidence of hypoglycemia or dose, and the mechanisms underlying the positive weight effects of detemir compared with NPH or glargine are currently unknown. Hypotheses include that insulin detemir may affect satiety signaling and energy homeostasis or that detemir’s albumin-binding properties may allow a greater exposure of detemir to the liver and less to peripheral adipose tissue, which could limit adipogenesis. However, these findings have not been confirmed and the proposed mechanisms are so speculative and so varied in nature that researchers are unsure as to which direction to follow to further elucidate the question.

Questions regarding the association of long-acting insulin analogs and induction of cancer have been investigated. According to a 2010 consensus statement issued by the ADA and the American Cancer Society (ACS), cancer and diabetes are diagnosed within the same individual more frequently than would be expected by chance, even after adjusting for age. The statement notes that, according to preliminary evidence, an association exists between exogenous insulin and increased cancer risk, and identifies a series of “widely publicized” epidemiologic analyses that examined a potential association between cancer and insulin use and/or use of the long-acting insulin analog glargine. The statement acknowledges the likelihood that confounding by unmeasured or incompletely measured risk factors may explain at least in part the reported associations between insulin and increased cancer risk, and describes a 5-year trial of glargine vs NPH (\( n = 1017 \)) that did not find evidence of excess cancer risk with glargine, although the number of cancer endpoints (57 glargine, 62 NPH), the statement notes, was small. The ADA/ACS statement ultimately recommends that cancer risk should not be a major factor in choosing between available diabetes therapies for the average patient. A meta-analysis by Dejgaard et al., not cited in the position statement, evaluated data from 8693 patients with type 1 or type 2 diabetes enrolled in randomized and controlled diabetes trials of at least 12 weeks in duration that compared detemir with NPH or glargine. The estimated OR for a cancer diagnosis between NPH and detemir was statistically significant and favored detemir. There was a more than twofold higher cancer occurrence in the NPH-treated population compared with detemir and a similar occurrence of a cancer diagnosis compared with glargine.

**Holistic approach to T2DM management**

Evidence supports a holistic approach to diabetes management using multidisciplinary teams that include a diabetes
specialist nurse, psychologist, nutritionist, and pharmacist to best address the complex medical care of patients with T2DM. The Global Partnership for Effective Diabetes Management is a multidisciplinary group of international diabetes experts that strives to provide guidance and support for diabetes management teams to help more patients achieve treatment goals. The group is focused on increasing awareness of current treatment guidelines and encouraging implementation of these guidelines in the clinical practice setting. A holistic approach is one of the 10 key practical recommendations of the Global Partnership for Effective Diabetes Management. In addition to controlling hyperglycemia, therapies directed at controlling other coexisting conditions of T2DM, such as dyslipidemia, hypertension, and obesity, may decrease the risk of developing microvascular and cardiovascular complications. Selecting therapies that minimize weight gain may help to reduce the barriers that prevent patients with T2DM from initiating or complying with insulin therapy (described in detail in a 2009 review by FX Pi-Sunyer) and support a holistic approach to treatment. Multidisciplinary group members should encourage structured patient education and self-care so responsibility for achieving agreed glucose and comorbid condition treatment goals is shared.

Conclusion

Protocols for some earlier clinical studies of detemir evaluated twice-daily dosing of detemir; this may have influenced clinical practice and clinician perception that detemir should be prescribed this way for all patients. However, detemir is FDA-approved for once-daily dosing in patients with T2DM or T1DM. The efficacy, safety, and feasibility of once-daily dosing of detemir are supported by glucose clamp study data and clinical trials, Results from the European cohorts of the observational PREDICTIVE study indicate that once-daily detemir is more commonly used in clinical practice than twice-daily dosing. In addition, once-daily detemir is as effective as twice-daily dosing in providing glycemic control and generally requires the use of less detemir insulin. Data show that once-daily detemir controls A1C and is associated with no weight gain or less weight gain than comparator regimens. Weight gain could make it more difficult to achieve glycemic control and exacerbate preexisting cardiovascular risk factors. Involvement of a multidisciplinary team and using a holistic approach for the treatment of T2DM patients are recommended to achieve and maintain the best patient outcomes. Adding a prandial insulin to the regimen before considering detemir twice daily may provide better glycemic control for patients who have not achieved glycemic control with a basal dose of once-daily detemir.

Acknowledgments

The author would like to thank Beatriz Manzor Mitzyk, PharmD, of MedVal Scientific Information Services, LLC, for providing writing and editorial assistance. This manuscript was prepared according to the International Society for Medical Publication Professionals’ Good Publication Practice for Communicating Company-Sponsored Medical Research: the GPP2 Guidelines. Funding to support the preparation of this manuscript was provided by Novo Nordisk Inc.

Disclosure

The author has no potential conflicts of interest to report in relation to this paper.

References

3. Humulin® N (NPH human insulin [rDNA origin]) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2009.


34. Meneghini LF, Rosenberg KH, Koenen C, Luddeke HJ. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab. 2007;9:418–427.


47. Dornhorst A, Luddeke HJ, Koenen C, et al. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE. *Diabetes Obes Metab.* 2008;10:75–81.